Pier Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Pier Capital’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-61,028	Closed	-$5.95M	–	137
2015 Q1	$5.95M	Buy	61,028 +23,723	+64%	+$2.51M	0.9%	78
2014 Q4	$3.46M	Sell	37,305 -2,341	-6%	-$185K	0.51%	93
2014 Q3	$2.73M	Sell	39,646 -43,847	-53%	-$3.14M	0.44%	96
2014 Q2	$8.75M	Buy	83,493 +5,707	+7%	+$486K	1.24%	17
2014 Q1	$6.45M	Buy	+77,786	New	+$7.19M	0.83%	77

Pier Capital's GEVA Position: Q2 2015 in Review

Pier Capital sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 61,028 shares — an estimated $5.95M sold.

Pier Capital first reported a position in GEVA in Q1 2014 and held it in 5 quarters. The position peaked at $8.75M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Pier Capital reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Pier Capital sold 61,028 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $5.95M.
Pier Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 5 quarters.
Pier Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $8.75M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Pier Capital's 13F filing for Q2 2015, filed 12 Aug 2015.